0001415889-24-011064.txt : 20240417 0001415889-24-011064.hdr.sgml : 20240417 20240417202117 ACCESSION NUMBER: 0001415889-24-011064 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240415 FILED AS OF DATE: 20240417 DATE AS OF CHANGE: 20240417 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Syntone Ventures LLC CENTRAL INDEX KEY: 0001814394 ORGANIZATION NAME: STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37759 FILM NUMBER: 24852555 BUSINESS ADDRESS: STREET 1: 1517 CHAMPLAIN CREST WAY CITY: CARY STATE: NC ZIP: 27513 BUSINESS PHONE: 781-308-0823 MAIL ADDRESS: STREET 1: 1517 CHAMPLAIN CREST WAY CITY: CARY STATE: NC ZIP: 27513 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Outlook Therapeutics, Inc. CENTRAL INDEX KEY: 0001649989 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 383982704 STATE OF INCORPORATION: DE FISCAL YEAR END: 0930 BUSINESS ADDRESS: STREET 1: 485 ROUTE 1 SOUTH STREET 2: BUILDING F, SUITE 320 CITY: ISELIN STATE: NJ ZIP: 08830 BUSINESS PHONE: 6096193990 MAIL ADDRESS: STREET 1: 485 ROUTE 1 SOUTH STREET 2: BUILDING F, SUITE 320 CITY: ISELIN STATE: NJ ZIP: 08830 FORMER COMPANY: FORMER CONFORMED NAME: Oncobiologics, Inc. DATE OF NAME CHANGE: 20150804 4 1 form4-04182024_120410.xml X0508 4 2024-04-15 0001649989 Outlook Therapeutics, Inc. OTLK 0001814394 Syntone Ventures LLC 1517 CHAMPLAIN CREST WAY CARY NC 27513 false false true false 0 Common Stock 2024-04-15 4 P 0 714286 A 1705438 D Warrant (Right to Buy) 7.70 2024-04-15 4 P 0 1071429 A 2024-04-15 2029-04-15 Common Stock 1071429 1071429 D Acquired in a private placement transaction pursuant to the terms of the Securities Purchase Agreement (the "SPA"), dated as of January 22, 2024, between Outlook Therapeutics, Inc. (the "Issuer") and Syntone Ventures LLC ("Syntone"), pursuant to which the Issuer sold shares of common stock, and, for each such share of common stock, accompanying warrants to purchase up to one and a half shares of common stock, at a purchase price of $7.00 per share and accompanying warrant. Under the SPA, Syntone purchased 714,286 shares of common stock and warrants to acquire 1,071,429 shares of common stock closed on April 15, 2024. Effective March 14, 2024, every 20 issued and outstanding shares of the Issuer's common stock was automatically combined into one issued and outstanding share of the Issuer's common stock (the "Reverse Stock Split"). Prior to the Reverse Stock Split, Syntone held 19,823,045 shares of common stock and, as a result of the Reverse Stock Split, such shares of common stock became 991,152 shares of common stock. /s/ Jiahui Zheng, Attorney-in-Fact 2024-04-17